Aggressive smaller players are serving a bitter pill to the big boys in the pharmaceutical sector.
At a time when pharmaceutical companies are investing billions of dollars to develop new and path-breaking medicines, it is the old and heritage brands that continue to dominate the market. Sales in 2011 show that the average age of the top 10 pharma brands is 19.3 years, and some of them are as old as 25 years.
Unhappy with Chinese machinery and raw materials they have been importing so far, Pakistani pharmaceutical companies are now longing to increase their business ties with India, and asked New Delhi to relax the "stringent visa norms".
The transaction, to be followed up by an open offer, puts the entire deal value between $3.4 billion and $4.6 billion.
Experts said it is the first time that an Indian pharmaceutical company has been charged with such serious offences, and that the firm may be prosecuted if the allegations are proved. Able Labs of the US, now a unit of Sun Pharma through an acquisition in 2005, had to face similar charges in 2004-2005.
Pharma major Ranbaxy on Thursday reported a 170 per cent rise in net profit at Rs 186 crore (Rs 1.86 billion) for the fourth quarter ended December 31, 2006
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Investors in Ranbaxy Laboratories got richer by over Rs 1,900 crore (Rs 19 billion) in a single day as the scrip surged by a little over 20 per cent on the Bombay Stock Exchange on Monday, a day after the pharma major announced a change of guard at its top management level.
Indian pharma firms under European drug regulator's scanner.
Ranbaxy Laboratories, Dr Reddy's, Nicholas Piramal and three other Indian drug companies cut their research costs by separating the units involved in developing new drugs, thereby addressing investor concerns on low operating margins.
.jpg)
The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.
Engineering major BHEL rebounded from its day's lows to end around 1% higher.
Ranbaxy, its partners and Actavis have signed a non-exclusive agreement.
Among the index heavyweights, Reliance Industries ended down 1.9% while mortage lender HDFC eased 0.2%. FMCG major ITC ended down 1.3%.
Brokerages have cut the company's FY16 earnings estimates between 16% and 29% with target prices too coming down to the Rs 700-800 band
Sun Pharma profit down 30% over compliance costs, lower sales.
FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.
The stock faced similar trends on the National Stock Exchange as well, where it opened at Rs 362, then plunged 2.70 per cent to an early low of Rs 354.10.
After decades of hunt for fortune abroad, India's pharmaceutical companies now plan to strike gold in their own backyard. Large players from Ranbaxy to Dr Reddy's and Piramal Healthcare are all headed to rural India to boost their revenues.
The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality drug payoffs.
This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
4 Ranbaxy facilities in India have been barred from exporting to US.
Teva Pharmaceutical Industries Ltd has sued Indian drug makers, including Ranbaxy Laboratories and Dr Reddy's, for alleged patent violation of ingredients used in Coreg, used for treatment of cardiovascular diseases.
Cipla tops pharma rankings with 5.42% market share, ahead of Ranbaxy and GSK.
Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.
Recently, Ranbaxy and Wockhardt too were hauled up.
Major Indian drug companies such as Ranbaxy Laboratories, Lupin, Dr Reddy's Laboratories and Glenmark have gone off the beaten track in overseas markets.
NPPA suggests expanding the list of essential medicines whose prices are controlled
I would focus on R&D, correct or fine tune the US strategy and look at inorganic growth routes
With local companies facing stress in domestic operations, valuations are down.
Pharmaceutical patents are just over a fourth of all patents granted in the country, but domestic drug makers account for almost all post-grant patent opposition filed, official data reveals.
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
The Sensex ended up 244 points at 28,504 on strong global cues.
He has already spearheaded eight significant acquisitions within and outside the country
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
For Sun Pharma, it is an astute purchase that it hopes will not only boost its position in India but also globally.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances